Annual report for Orchid Pharma Ltd. for FY-2020
30-06-2020
Orchid Pharma Ltd - 524372 - Audited Financial Results For The Finanacial Year Ended March 31,2020
Audited financial results for the Finanacial year ended March 31,202029-06-2020
Orchid Pharma Ltd - 524372 - Approval Of Audited Financial Results For The FY 2019-2020
Approval of Audited financial results for the FY 2019-202029-06-2020
Orchid Pharma Ltd - 524372 - Board Meeting Intimation for Consideration And Approval Of Audited Standalone And Consolidated Financial Statements For The Fourth Quarter And Year Ended March 31,2020
Orchid Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/06/2020 ,inter alia, to consider and approve Audited Standalone and Consolidated financial statements for the fourth quarter and year ended March 31,202026-06-2020
Covid-19: Mumbaiites rent oxygen cylinders, wait for ICU beds
We have got two oxygen cylinders in our society, we decided to get it after seeing how people are being turned away from hospitals due to lack of beds. We have a doctor in our complex and we have learnt how to operate it, said Salim Motorwala a resident of Orchid Towers in Mumbai Central.27-05-2020
Orchid Pharma Ltd - 524372 - Compliance Certificate Under Regulation 7(3) Of SEBI (LODR) Regulations,2015 For The Half Year Ended March 31,2020
Compliance certificate under Regulation 7(3) of SEBI (LODR) Regulations,2015 for the half year ended March 31,202024-05-2020
Orchid Pharma Ltd - 524372 - Certificate Under Regulation 40(10) Of The SEBI(LODR)Regulations,2015
Certificate under Regulation 40(10) of the SEBI(LODR)Regulations,201523-05-2020
Orchid Pharma Ltd - 524372 - Shareholding for the Period Ended March 31, 2020
Orchid Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2020. For more details, kindly Click here15-05-2020
Orchid Pharma Ltd - 524372 - Statement Of Investor Complaints For The Quarter Ended March 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0330 Name of the Signatory :- NIKITA KDesignation :- Company Secretary and Compliance Officer13-05-2020
Orchid Pharma Ltd - 524372 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Dhanuka Laboratories Ltd08-04-2020